The Earnings Debate
Medtronic reported "$9.8 billion in revenue" for the fourth quarter of fiscal 2026, up "9.9% on a reported basis and 6.6% organically." For the full fiscal year, the company "delivered 36.4billioninrevenue."MedtronicreportedfourthquarteradjustedEPSof"1.55" and full fiscal year 2026 adjusted EPS of "$5.53." The company also reported an "adjusted gross margin was 65.4%" for the quarter and an "adjusted operating margin of 25.5%." "Free cash flow was $5.4 billion in fiscal year '26."Management highlighted strong execution across the business, noting that within Cardiac Ablation Solutions, "PFA saw exceptional global growth of 145% with Sphere-9." The company also highlighted its Symplicity Spyral therapy, noting it is "annualizing at $100 million." During the quarter, Medtronic "completed the MiniMed IPO, establishing it as a stand-alone publicly traded company."In product and M&A news, the company "submitted to the FDA for 510(k) clearance for general surgery and gynecologic indications, as well as for our LigaSure RAS vessel sealer" for the Hugo surgical robotic system. Medtronic also "closed on the Cath works transaction" and "announced plans to acquire Scientia, an SPR Therapeutics as well as investments in Beluga Medical and CardioACC."For forward guidance, Medtronic is guiding "fiscal year '27 organic revenue growth of 6.75% to 7.25%, including approximately 11.5% to 12% organic growth in the first quarter." The company is "guiding '27 EPS of $5.90 to $6." For the first quarter, management expects "EPS in the range of $1.38 to $1.40." Overall, the company expects "fiscal '27 operating margin to be up 60 basis points."
199 afleveringen
Reacties
0Wees de eerste die een reactie plaatst
Meld je nu aan en word lid van de The Earnings Debate community!